Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yupingfeng Powder with Variation for Allergic Rhinitis
NCT06608017Phase 3Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of yupingfeng oral solution in allergic rhinitis (AR), sponsored by The Chinese University of Hong Kong. Started Mar 2025; status: recruiting.
02
Drugs
yupingfeng oral solution
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06608017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608017.